Physician profile
Robert Ortiz
NPI 1255384418
$5,755.72
in general payments reported to CMS, 2019-2025
31 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $434 · 2021: $355 · 2022: $745 · 2023: $1,181 · 2024: $1,055 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,794.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $1,289.66 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Novo Nordisk INC | $1,014.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $587.00 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $501.98 | 2022-2025 | |
| Insulet Corporation | $310.44 | 2021-2025 | Omnipod, Omnipod |
| Medtronic, INC. | $304.47 | 2021-2025 | Minimed 780g, Minimed 630g |
| Halozyme INC | $269.06 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $202.38 | 2019-2023 | Farxiga, Lokelma |
| Abbott Laboratories | $196.97 | 2022-2025 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $122.48 | 2020 | |
| Corcept Therapeutics | $97.24 | 2025 | Korlym |
| Recordati_rare_diseases_inc. | $91.99 | 2022-2024 | Signifor Lar, Isturisa |
| Amneal Pharmaceuticals LLC | $77.94 | 2023-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $74.24 | 2019 | |
| Dexcom, INC. | $74.22 | 2022-2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.25 | 2023-2025 | Jardiance, Synjardy, Glyxambi |
| Ibsa Pharma INC. | $63.47 | 2023-2024 | Tirosint, Licart, Licart |
| Viiv Healthcare Company | $53.36 | 2025 | Apretude |
| Tandem Diabetes Care, INC. | $50.07 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $45.53 | 2025 | |
| Glaxosmithkline, LLC. | $36.36 | 2021 | |
| Ionis Pharmaceuticals, INC. | $30.54 | 2025 | Tryngolza |
| Sequel Med Tech, LLC | $29.24 | 2025 | Twiist |
| Tactile Systems Technology INC | $28.88 | 2024 | Entre Plus, Flexitouch Plus |
| Amgen INC. | $25.08 | 2025 | Tepezza |
| Eusa Pharma (US) LLC | $24.33 | 2022 | |
| W. L. Gore & Associates, INC. | $23.53 | 2023 | Gore Viabahn Endoprosthesis With Heparin |
| Abbvie INC. | $17.80 | 2023 | |
| Intuity Medical INC | $15.98 | 2022 | |
| Pfizer INC. | $14.85 | 2022 | |
| Endo Pharmaceuticals INC. | $14.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.